American College of Radiology  
ACR Appropriateness Criteria®  

Localized Nodal Indolent Lymphoma  

**Variant 1:** 58-year-old woman with stage IA follicular lymphoma (grade 1 or 2) involving multiple 2 cm lymph nodes in the right cervical neck.

<table>
<thead>
<tr>
<th>Procedure</th>
<th>Appropriateness Category</th>
<th>SOE</th>
<th>Adults RRL</th>
<th>Peds RRL</th>
<th>Rating</th>
<th>Median</th>
<th>Final Tabulations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chemotherapy alone</td>
<td>Usually not appropriate</td>
<td>TBD TBD</td>
<td>2</td>
<td>n/a</td>
<td>0</td>
<td>0</td>
<td>0 0 0 0 0 0 0 0 0</td>
</tr>
<tr>
<td>Immunotherapy alone</td>
<td>May be appropriate</td>
<td>4</td>
<td>n/a</td>
<td>0 0 0 0 0 0 0 0 0</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chemotherapy and immunotherapy</td>
<td>Usually not appropriate</td>
<td>3</td>
<td>n/a</td>
<td>0 0 0 0 0 0 0 0 0</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Radioimmunotherapy alone</td>
<td>Usually not appropriate</td>
<td>2</td>
<td>n/a</td>
<td>0 0 0 0 0 0 0 0 0</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chemotherapy and immunotherapy followed by IFRT</td>
<td>May be appropriate</td>
<td>4</td>
<td>n/a</td>
<td>0 0 0 0 0 0 0 0 0</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Immunotherapy followed by IFRT (24-30 Gy)</td>
<td>May be appropriate</td>
<td>4</td>
<td>n/a</td>
<td>0 0 0 0 0 0 0 0 0</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Observation</td>
<td>May be appropriate</td>
<td>TBD TBD</td>
<td>4</td>
<td>n/a</td>
<td>0 0 0 0 0 0 0 0 0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>24-30 Gy</td>
<td>Usually appropriate</td>
<td>9</td>
<td>n/a</td>
<td>0 0 0 0 0 0 0 0 0</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>36-45 Gy</td>
<td>May be appropriate</td>
<td>4</td>
<td>n/a</td>
<td>0 0 0 0 0 0 0 0 0</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Procedure</td>
<td>Appropriateness Category</td>
<td>SOE</td>
<td>Adults RRL</td>
<td>Peds RRL</td>
<td>Rating</td>
<td>Median</td>
<td>Final Tabulations</td>
</tr>
<tr>
<td>------------------------------------------------</td>
<td>---------------------------------</td>
<td>--------------</td>
<td>------------</td>
<td>----------</td>
<td>--------</td>
<td>--------</td>
<td>------------------</td>
</tr>
<tr>
<td>4 Gy</td>
<td></td>
<td></td>
<td>4</td>
<td>n/a</td>
<td></td>
<td></td>
<td>0 0 0 0 0 0 0 0 0</td>
</tr>
<tr>
<td>Extended field radiotherapy (EFRT)</td>
<td>Usually not appropriate</td>
<td></td>
<td>1</td>
<td>n/a</td>
<td></td>
<td></td>
<td>0 0 0 0 0 0 0 0 0</td>
</tr>
<tr>
<td>Involved field radiotherapy (IFRT)</td>
<td>Usually appropriate</td>
<td></td>
<td>8</td>
<td>n/a</td>
<td></td>
<td></td>
<td>0 0 0 0 0 0 0 0 0</td>
</tr>
<tr>
<td>Involved node radiotherapy (INRT)</td>
<td>Usually not appropriate</td>
<td></td>
<td>3</td>
<td>n/a</td>
<td></td>
<td></td>
<td>0 0 0 0 0 0 0 0 0</td>
</tr>
</tbody>
</table>

Variant 2: 67-year-old man with stage IIA follicular lymphoma (grade 2) involving the right inguinal and right internal iliac nodes (2-3 cm in size).
<table>
<thead>
<tr>
<th>Procedure</th>
<th>Appropriateness Category</th>
<th>SOE</th>
<th>Adults RRL</th>
<th>Peds RRL</th>
<th>Rating</th>
<th>Median</th>
<th>Final Tabulations</th>
</tr>
</thead>
<tbody>
<tr>
<td>chemotherapy alone</td>
<td>Usually not appropriate</td>
<td>TBD</td>
<td>TBD</td>
<td>n/a</td>
<td>2</td>
<td>n/a</td>
<td>0 0 0 0 0 0 0 0 0</td>
</tr>
<tr>
<td>immunotherapy alone</td>
<td>Usually not appropriate</td>
<td>3</td>
<td>n/a</td>
<td>0 0 0 0 0 0 0 0 0</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>chemotherapy and immunotherapy</td>
<td>Usually not appropriate</td>
<td>3</td>
<td>n/a</td>
<td>0 0 0 0 0 0 0 0 0</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>radioimmunotherapy alone</td>
<td>Usually not appropriate</td>
<td>2</td>
<td>n/a</td>
<td>0 0 0 0 0 0 0 0 0</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>chemotherapy and immunotherapy followed by IFRT (24-30 Gy)</td>
<td>Usually not appropriate</td>
<td>2</td>
<td>n/a</td>
<td>0 0 0 0 0 0 0 0 0</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>immunotherapy followed by IFRT (24-30 Gy)</td>
<td>Usually not appropriate</td>
<td>3</td>
<td>n/a</td>
<td>0 0 0 0 0 0 0 0 0</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Variant 3: 35-year-old woman with stage IA follicular lymphoma (grade 1) involving a single 2.8 cm lymph node in the axilla that was removed at the biopsy with no evidence of residual adenopathy.
## Variant 4: 80-year-old symptomatic woman with stage IIB bulky (12 cm) follicular lymphoma involving the mesentery and para-aortics.

<table>
<thead>
<tr>
<th>Procedure</th>
<th>Appropriateness Category</th>
<th>SOE</th>
<th>Adults RRL</th>
<th>Peds RRL</th>
<th>Rating</th>
<th>Median</th>
<th>Final Tabulations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chemotherapy alone</td>
<td>Usually not appropriate</td>
<td>TBD TBD</td>
<td>3</td>
<td>n/a</td>
<td>0</td>
<td>0</td>
<td>0 0 0 0 0 0 0 0</td>
</tr>
<tr>
<td>Immunotherapy alone</td>
<td>May be appropriate</td>
<td></td>
<td>4</td>
<td>n/a</td>
<td>0</td>
<td>0</td>
<td>0 0 0 0 0 0 0 0</td>
</tr>
<tr>
<td>Chemotherapy and immunotherapy</td>
<td>Usually appropriate</td>
<td></td>
<td>7</td>
<td>n/a</td>
<td>0</td>
<td>0</td>
<td>0 0 0 0 0 0 0 0</td>
</tr>
<tr>
<td>Radioimmunotherapy alone</td>
<td>Usually not appropriate</td>
<td></td>
<td>3</td>
<td>n/a</td>
<td>0</td>
<td>0</td>
<td>0 0 0 0 0 0 0 0</td>
</tr>
<tr>
<td>Chemotherapy and immunotherapy followed by IFRT (24-30 Gy)</td>
<td>Usually appropriate</td>
<td></td>
<td>8</td>
<td>n/a</td>
<td>0</td>
<td>0</td>
<td>0 0 0 0 0 0 0 0</td>
</tr>
</tbody>
</table>
### Immunotherapy followed by IFRT (24-30 Gy)
May be appropriate

<table>
<thead>
<tr>
<th>Procedure</th>
<th>Appropriateness Category</th>
<th>SOE</th>
<th>Adults RRL</th>
<th>Peds RRL</th>
<th>Rating</th>
<th>Median</th>
<th>Final Tabulations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Immunotherapy followed by IFRT (24-30 Gy)</td>
<td>May be appropriate</td>
<td></td>
<td></td>
<td></td>
<td>5</td>
<td>n/a</td>
<td>0 0 0 0 0 0 0 0 0 0 0 0 0 0</td>
</tr>
<tr>
<td>Observation</td>
<td>Usually not appropriate</td>
<td>TBD TBD</td>
<td></td>
<td></td>
<td>1</td>
<td>n/a</td>
<td>0 0 0 0 0 0 0 0 0 0 0 0 0 0</td>
</tr>
<tr>
<td>24-30 Gy</td>
<td>May be appropriate</td>
<td></td>
<td></td>
<td></td>
<td>6</td>
<td>n/a</td>
<td>0 0 0 0 0 0 0 0 0 0 0 0 0 0</td>
</tr>
<tr>
<td>36-45 Gy</td>
<td>May be appropriate</td>
<td></td>
<td></td>
<td></td>
<td>6</td>
<td>n/a</td>
<td>0 0 0 0 0 0 0 0 0 0 0 0 0 0</td>
</tr>
<tr>
<td>4 Gy</td>
<td>May be appropriate</td>
<td></td>
<td></td>
<td></td>
<td>6</td>
<td>n/a</td>
<td>0 0 0 0 0 0 0 0 0 0 0 0 0 0</td>
</tr>
<tr>
<td>Extended field radiotherapy (EFRT)</td>
<td>Usually not appropriate</td>
<td></td>
<td></td>
<td></td>
<td>2</td>
<td>n/a</td>
<td>0 0 0 0 0 0 0 0 0 0 0 0 0 0</td>
</tr>
<tr>
<td>Involved field radiotherapy (IFRT)</td>
<td>Usually appropriate</td>
<td></td>
<td></td>
<td></td>
<td>7</td>
<td>n/a</td>
<td>0 0 0 0 0 0 0 0 0 0 0 0 0 0</td>
</tr>
<tr>
<td>Involved node radiotherapy (INRT)</td>
<td>May be appropriate</td>
<td></td>
<td></td>
<td></td>
<td>6</td>
<td>n/a</td>
<td>0 0 0 0 0 0 0 0 0 0 0 0 0 0</td>
</tr>
</tbody>
</table>

**Variant 5:** 50-year-old man with chemotherapy- and immunotherapy-refractory stage IV follicular lymphoma with a 6 cm para-aortic nodal mass causing significant back pain.
| Treatment                                                                 | Appropriateness | Count | n/a | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
|--------------------------------------------------------------------------|-----------------|-------|-----|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Chemotherapy and immunotherapy followed by IFRT (24-30 Gy)               | Usually not appropriate | 3     | n/a | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Immunotherapy followed by IFRT (24-30 Gy)                                | Usually not appropriate | 3     | n/a | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Observation                                                              | Usually not appropriate | TBD   | TBD | 1 | n/a | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 24-30 Gy                                                                 | Usually appropriate | 8     | n/a | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 36-45 Gy                                                                 | May be appropriate | 6     | n/a | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 4 Gy                                                                     | Usually appropriate | 7     | n/a | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Extended field radiotherapy (EFRT)                                       | Usually not appropriate | 2     | n/a | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Involved field radiotherapy (IFRT)                                       | Usually appropriate | 7     | n/a | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Involved node radiotherapy (INRT)                                        | Usually appropriate | 8     | n/a | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Please refer to the supporting documentation for a more complete discussion of the concepts and their definitions below.

**Final Tabulations:**
A histogram of the number of panel members who rated the recommendation as noted in the column heading (ie, 1, 2, 3, …etc.)

**Disagree:**
The variation of the individual ratings from the median rating indicates panel disagreement on the final recommendation.

**References:**
Lists the references associated with the recommendation.

**SQ:**
Study Quality (1, 2, 3, 4, Good M or Inadequate M) of the references listed.

**RRL:**
Information on the Relative Radiation Level (RRL) designations can be found [here](#).